Results 191 to 200 of about 109,331 (244)

Orthogonal Light‐ and Enzyme‐Triggered and‐Gate Prodrugs for Senolytic Therapy

open access: yesAdvanced Science, EarlyView.
An orthogonal AND‐gate prodrug platform combines 390 nm near‐UV photocleavage with SA‐β‐gal activation to control payload release in senescent cells. Its modular architecture enables 4‐MU fluorescence, doxorubicin‐mediated cytotoxicity, and ARV‐771‐driven BRD4 degradation, supporting stimulus‐controlled senolytic design in cellular and organoid models.
Mengyang Chang   +12 more
wiley   +1 more source

Tumor‐Intrinsic HEXB Drives Endothelial‐To‐Mesenchymal Transition and Confers Resistance to Anti‐Angiogenic Therapy in Glioblastoma

open access: yesAdvanced Science, EarlyView.
This study elucidates how glioblastoma tumors develop resistance to anti‐VEGF therapy through endothelial‐to‐mesenchymal transition (Endo‐MT). The researchers identify a novel signaling pathway where tumor‐derived HEXB stabilizes HSP60 to drive this vascular reprogramming.
Tianqi Liu   +13 more
wiley   +1 more source

Hepatic Lipid Stress Drives Metabolic Dysfunction‐Associated Steatohepatitis Progression through FTO O‐GlcNAcylation‐Induced m6A Demethylation of HRAS

open access: yesAdvanced Science, EarlyView.
Lipid stress drives O‐GlcNAcylation of the m6A demethylase FTO at Ser195, enhancing its stability and demethylase activity. This modification removes m6A from HRAS mRNA, preventing its degradation and activating PI3K/AKT signaling to promote hepatic steatosis and inflammation.
Jia‐Xin Yin   +9 more
wiley   +1 more source

Development of Versatile Nanoparticle System for Efficient Drug Delivery into Pulmonary Endothelium

open access: yesAdvanced Science, EarlyView.
Pediatric acute respiratory distress syndrome (PARDS) suppresses the FOXF1 transcription factor and disrupts lung development. This study shows that the FOXF1‐activating small‐molecule compound, TanFe[F], can be precisely delivered to lung endothelial cells using the innovative LEDD nanoparticle system.
Afzaal N. Mohammed   +12 more
wiley   +1 more source

VCP‐Regulated LMF2 Stabilizes the Cholesterol Biosynthesis Enzyme HMGCS1 to Drive Cancer Progression and Confer Capecitabine Resistance in Triple‐Negative Breast Cancer

open access: yesAdvanced Science, EarlyView.
LMF2 drives progression and capecitabine resistance in triple‐negative breast cancer (TNBC). Mechanistically, VCP prevents NBR1‐mediated autophagic degradation of LMF2, thereby stabilizing it. Stabilized LMF2 subsequently suppresses NDP52‐mediated autophagic degradation of HMGCS1, a rate‐limiting cholesterol biosynthesis enzyme.
Qian Zhao   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy